2022
DOI: 10.1016/j.annonc.2022.02.051
|View full text |Cite
|
Sign up to set email alerts
|

42P Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles